AbbVie ABBV has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic areas. The company’s pipeline spans immunology therapies, expanding oncology ...

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with obesity, President Trump announced on Thursday. "Until now, neither of these ...

There is more than one way to blockbuster product sales, and sometimes smaller might be better, writes Bennett Smith.

Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...